Thursday, April 10, 2014

McCabe Pub hosts Crawfish Boil to Benefit the LAM Foundation

McCabe Pub hosts Crawfish Boil to benefit the LAM Foundation

 

McCabe Pub Crawfish Boil

 


             McCabe Pub will host its second annual crawfish boil on Saturday, April 19 from 3 – 8 p.m. in the parking lot of its Sylvan Park location at 4410 Murphy Road in Nashville.  The event will include all-you-can-eat crawfish and three drink tickets for $30 per person, a cash bar, live music and other entertainment. All proceeds will benefit the LAM Foundation, which seeks safe and effective treatments and ultimately a cure for lymphangioleiomyomatosis (LAM).  McCabe Pub’s co-owner, Stefanie Dean Brown, was diagnosed with LAM in October 2010 and continues treatment.
 
            “Many of our guests at McCabe Pub are longtime regulars, and they feel more like family than customers,” said Katie Dean, co-owner and Stefanie’s sister. “They know about Stefanie’s condition and have asked how they can help, so we started this annual fundraiser last year for the LAM Foundation to help find a cure for this disease.”
 
              Last year’s inaugural event raised more than $15,000 for the LAM Foundation, and this second annual event is expected to surpass last year’s totals. Tickets are available online at www.mccabepub.com, and will also be available at the door on event day, cash or check only.

 

About The LAM Foundation

The LAM Foundation is the global leader in the fight against Lymphangioleiomyomatosis (LAM). The Foundation began in 1995 as a grass roots effort and has evolved into an organization that is described by the National Heart, Lung, and Blood Institute (NHLBI) as "a model for voluntary health agencies." Headquartered in Cincinnati, Ohio, the Foundation embodies all of the elements required to move LAM research from the laboratory to the clinic. The Foundation embraces women with LAM and their families, provides support and education, engages doctors and scientists, and raises funds for the study of LAM. With the funding of promising research as our central mission, the Foundation has elevated LAM from the ranks of rare and forgotten diseases into the minds of many experts in pulmonary medicine. The LAM Foundation funded the first LAM research that resulted in the fundamental understanding of the genetic cause of LAM and the first ever LAM treatment trial. It is amazing how far LAM research has come in such a short period of time, thanks especially to the many researchers who have helped to make this disease a research priority. LAM and Tuberous Sclerosis researchers have identified a wealth of potential molecular targets and experimental therapies that may be appropriate for testing in clinical trials. Many of these drugs are FDA-approved or in development for other indications.



- Dr. April

No comments:

Post a Comment